With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors

Neurocrine's stock price took a tumble Friday after the company revealed its 2025 revenue forecast for its 2017-approved tardive dyskinesia med Ingrezza.

Related Posts

With plan to build 4 new plants, Eli Lilly doubles down...

Feb 26, 2025  0

Roche, Gilead top patient groups’ rankings of pharma ES...

Feb 28, 2025  0

Amid takeover talk, SpringWorks scores FDA nod for rare...

Feb 12, 2025  0

Comments

Name

Email

Comment

Post Comment